Apollomics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Apollomics Inc
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
/ 
Frequently asked questions
To buy Apollomics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Apollomics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Apollomics Inc is APLM:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Apollomics Inc has its primary listing on NASDAQ. You can trade Apollomics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Apollomics Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Apollomics Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Apollomics Inc.